The mechanism of action of docetaxel (Taxotere®) in xenograft models is not limited to bcl-2 phosphorylation Lisa Ann KrausShanti K. SamuelMarie Christine Bissery OriginalPaper Pages: 259 - 268
The alkylating agent penclomedine induces degeneration of purkinje cells in the rat cerebellum Seamus O'ReillyElizabeth O'HearnMark E. Molliver OriginalPaper Pages: 269 - 279
Immunomodulatory effects of docetaxel on human lymphocytes Ming-Sing SiDavid K. ImagawaDominic C. Borie OriginalPaper Pages: 281 - 290
Effect of valspodar on the pharmacokinetics of unbound paclitaxel Albert J. ten TijeTimothy W. SynoldAlex Sparreboom OriginalPaper Pages: 291 - 298
Phase I studies of weekly administration of cytotoxic agents: Implications of a mathematical model Donna K. McClishJohn D. Roberts OriginalPaper Pages: 299 - 308
Positron emission tomography (PET): Expanding the horizons of oncology drug development Lisa A. HammondLouis DenisJohn G. Kuhn OriginalPaper Pages: 309 - 340
Phase II trial of ZD1839 (IRESSA™) in patients with advanced renal cell carcinoma Beverly DruckerJennifer BacikRobert Motzer OriginalPaper Pages: 341 - 345
Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer* Christian DittrichVeronique DierasPierre Fumoleau OriginalPaper Pages: 347 - 352
A phase II trial of pemetrexed in patients with metastatic renal cancer R. ThödtmannT. SauterA.-R. Hanauske OriginalPaper Pages: 353 - 358
Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer Lissandra Dal LagoMarc F. RichterGilberto Schwartsmann OriginalPaper Pages: 359 - 366
Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer Glenn LiuKurt OettelGeorge Wilding OriginalPaper Pages: 367 - 372
A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: A Gynecologic Oncology Group Study Deborah K. ArmstrongJohn A. BlessingEvelyn R. Nunez OriginalPaper Pages: 373 - 377